Treatment strategies considering micro-environment and clonal evolution in multiple myeloma
K Suzuki, K Nishiwaki, S Yano - Cancers, 2021 - mdpi.com
Simple Summary Multiple myeloma is an uncurable hematological malignancy, although the
prognosis of myeloma patients is getting better using proteasome inhibitors (PIs), immune …
prognosis of myeloma patients is getting better using proteasome inhibitors (PIs), immune …
The emerging treatment options of plasmablastic lymphoma: analysis of 173 individual patient outcomes
Plasmablastic lymphoma (PBL) is a newly recognized aggressive subtype of non-Hodgkin
lymphoma. Its rarity hinders testing effective treatment options in clinical trials. We conducted …
lymphoma. Its rarity hinders testing effective treatment options in clinical trials. We conducted …
Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data
A Mosquera Orgueira, MS González Pérez… - Leukemia, 2021 - nature.com
Multiple myeloma (MM) remains mostly an incurable disease with a heterogeneous clinical
evolution. Despite the availability of several prognostic scores, substantial room for …
evolution. Despite the availability of several prognostic scores, substantial room for …
Dynamic single-cell RNA-seq analysis reveals distinct tumor program associated with microenvironmental remodeling and drug sensitivity in multiple myeloma
M Chen, Y Wan, X Li, J Xiang, X Chen, J Jiang, X Han… - Cell & Bioscience, 2023 - Springer
Background Multiple myeloma (MM) is a hematological malignancy characterized by clonal
proliferation of malignant plasma cells. Despite extensive research, molecular mechanisms …
proliferation of malignant plasma cells. Despite extensive research, molecular mechanisms …
Single-cell analysis of multiple myelomas refines the molecular features of bortezomib treatment responsiveness
Both the tumor and tumor microenvironment (TME) are crucial for pathogenesis and
chemotherapy resistance in multiple myeloma (MM). Bortezomib, commonly used for MM …
chemotherapy resistance in multiple myeloma (MM). Bortezomib, commonly used for MM …
A network analysis of multiple myeloma related gene signatures
Multiple myeloma (MM) is the second most prevalent hematological cancer. MM is a
complex and heterogeneous disease, and thus, it is essential to leverage omics data from …
complex and heterogeneous disease, and thus, it is essential to leverage omics data from …
[HTML][HTML] The combination of WGS and RNA-Seq is superior to conventional diagnostic tests in multiple myeloma: Ready for prime time?
A Höllein, SO Twardziok, W Walter, S Hutter, C Baer… - Cancer genetics, 2020 - Elsevier
The diagnosis and risk stratification of multiple myeloma (MM) is based on clinical and
cytogenetic tests. Magnetic CD138 enrichment followed by interphase FISH (fluorescence in …
cytogenetic tests. Magnetic CD138 enrichment followed by interphase FISH (fluorescence in …
Gene networks constructed through simulated treatment learning can predict proteasome inhibitor benefit in multiple myeloma
J Ubels, P Sonneveld, MH van Vliet, J de Ridder - Clinical Cancer Research, 2020 - AACR
Purpose: Proteasome inhibitors are widely used in treating multiple myeloma, but can cause
serious side effects and response varies among patients. It is, therefore, important to gain …
serious side effects and response varies among patients. It is, therefore, important to gain …
Highly expressed genes in multiple myeloma cells–what can they tell us about the disease?
M Børset, S Elsaadi, EN Vandsemb… - European Journal of …, 2022 - Wiley Online Library
Cancer cells can convert proto‐oncoproteins into oncoproteins by increasing the expression
of genes that are oncogenic when expressed at high levels. Such genes can promote …
of genes that are oncogenic when expressed at high levels. Such genes can promote …
[HTML][HTML] Activated interferon response from DNA damage in multiple myeloma cells contributes to the chemotherapeutic effects of anthracyclines
J Li, Z Jia, R Wang, B Xiao, Y Cai, T Zhu… - Frontiers in …, 2024 - ncbi.nlm.nih.gov
Methods Gene Ontology (GO) analysis with differentially expressed genes was performed to
identify signal pathway. Drug sensitivity was analyzed using the OncoPredict algorithm …
identify signal pathway. Drug sensitivity was analyzed using the OncoPredict algorithm …